Prospective, Open-Label, Observational, Multicenter, Single Arm, Post-Marketing Study in Asthmatic Patients for Evaluation of Safety and Effectiveness of Indacaterol/Mometasone DPI (PROMISING-SHIFT)
Authors:
- Saurabh KarmakarSKSaurabh Karmakar
- Gajendra V. SinghGSGajendra V. Singh
- Amit S. BhateABAmit S. Bhate
- Vijaykumar BargeVBVijaykumar Barge
- Bharat MehrotraBMBharat Mehrotra
- Chintan PatelCPChintan Patel
- Ekta SinhaESEkta Sinha
- Sagar BhagatSBSagar Bhagat
- Saiprasad PatilSPSaiprasad Patil
- Hanmant BarkateHBHanmant Barkate
Open Access
- 6 February 2025
- journal article
- research article
- Published by MDPI AG in Advances in Respiratory Medicine
- Vol. 93 (1) , 3
Abstract
Background: Asthma significantly impacts global health, necessitating effective management strategies. A combination of inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABA) is recommended for patients with inadequately controlled asthma. Method: This prospective, open-label, multicenter study (PROMISING-SHIFT) study evaluated the safety and efficacy of once-daily Indacaterol/Mometasone (IND/MF) dry powder inhaler (DPI) in Indian asthma patients (≥12 years), inadequately controlled with prior therapies. Patients received IND/MF DPI in three strengths (150/80 mcg, 150/160 mcg, 150/320 mcg) over 12 weeks. Results: The study included a total of 174 participants, and 27 adverse events (AEs) in 25 patients (14.37%) were reported, primarily mild to moderate, with no serious adverse events (SAEs). Drug-related treatment-emergent adverse events (TEAEs) were observed in 11 patients. Significant improvements were noted in the mean trough FEV1 and FVC, increasing from baseline to week 4 and week 12 (p < 0.001). The mean ACQ-5 score significantly decreased from 3.0 ± 0.73 baseline to 2.50 ± 0.53 (16.67%) at week 4 and further to 1.73 ± 0.35 at week 12, along with reduced exacerbations (p < 0.001). The need for rescue medication declined from 13.79% to 8.62%, and 96.55% of patients reported treatment satisfaction by study completion. Conclusion: Once-daily IND/MF DPI demonstrated a favorable safety profile with marked improvements in lung function, asthma control, and patient satisfaction, making it a promising option for long-term asthma management in Indian patients.Keywords
Funding Information
- Glenmark Pharmaceutical Ltd., India
This publication has 11 references indexed in Scilit:
- Beyond direct costs: individual and societal financial burden of asthma in young adults in a Danish nationwide studyBMJ Open Respiratory Research, 2023
- Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM studyRespiratory Medicine, 2023
- Pathophysiology of Asthma-Chronic Obstructive Pulmonary Disease OverlapImmunology and Allergy Clinics of North America, 2022
- Prevalence, time trends and treatment practices of asthma in India: the Global Asthma Network studyERJ Open Research, 2022
- One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studiesBMJ Open Respiratory Research, 2021
- Once-daily, single-inhaler indacaterol/mometasone versus twice-daily salmeterol/fluticasone in Asian patients with inadequately controlled asthma: post hoc pooled analysis from PALLADIUM and IRIDIUM studiesJournal of Asthma, 2021
- Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 studyThe Lancet Respiratory Medicine, 2020
- Treatment strategies for asthma: reshaping the concept of asthma managementAllergy, Asthma & Clinical Immunology, 2020
- Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findingsRespiratory Medicine, 2020
- Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchiEuropean Respiratory Journal, 2006